Carvykti now second-biggest seller among CAR Ts
Yescarta still the market leader by a wide margin, as Carvykti, Abecma, Breyanzi await label expansions
Sales of Carvykti, the newest entrant to the CAR T market, have surpassed those of four older CAR T therapies to position the product as the modality’s second-biggest seller, after market leader Yescarta. A PDUFA date in April could further propel Carvykti’s growth.
Since its U.S. approval for fifth-line multiple myeloma in February 2022, sales of Carvykti ciltacabtagene autoleucel, a BCMA-targeted CAR T therapy from Johnson & Johnson (NYSE:JNJ) and Legend Biotech Corp. (NASDAQ:LEGN), have been steadily climbing, and in the third quarter of last year, they surpassed those of direct competitor Abecma idecabtagene vicleucel from Bristol Myers Squibb Co. (NYSE:BMY) and 2seventy bio Inc. (NASDAQ:TSVT). Abecma, also a BCMA-targeted CAR T, was approved for the same indication in March 2021. ...